Guardant Health (GH) Tops Q1 EPS by 26c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
April 30, 2025 4:05 PM EDTRevenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data
Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20%
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights
For the three-month period ended March 31, 2025, as compared to the same period of 2024:
Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of... More